Phase IIa diabetes study termination

We have succesfully finished clinical part of phase II study with patients suffered from diabetes type II.
 
The aim of the study was to assess safety and efficacy of oral administration of IMP (different doses for each arm including placebo) accompanied to standard treatment, once daily for 14 consecutive days. 80 patients in total were enrolled. No drug related serious adverse events were recorded.

Go back

News

First phase study

We have just succesfully finished the second part of the first phase study with no Serious Adverse Events.

Read more …

Bioequivalence study

We have just finished clinical part of one of our ongoing bioequivalence Clinical Studies.

Read more …

Membership in SCRS

We have joined the Society for Clinical Research Sites (SCRS)!

 

Read more …

Open Recruitment to new study

We have started new study with testosterone for healthy Volunteers or Patients with testosterone deficiency.

Read more …

FIM study

We have just succesfully finished First in Man study with psychoactive substance.

Read more …

About Us | Services | Our Site | Partners | Smoking Risk Study | Contact Us

Early Phase Clinical Trials

2025 © Bio Research Group. All rights reserved.

 

scroll to top ▲